home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
Post navigation
Previous Post
Previous
Kronos Bio Announces Participation in Upcoming Investor Conferences
Next Post
Next
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference